Vaidya Sane Ayurved Laboratories (Madhavbaug) H1 FY26 Concall Decoded – From Panchakarma to Profit Karma
1. Opening Hook
Ayurveda just went corporate—complete with EBITDA targets, insurance tie-ups, and international ambitions. Dr. Rohit Sane’s Madhavbaug wants to reverse diseases and investor skepticism at once. With 320 clinics, 4 hospitals, and a Sonu Sood ad campaign, this Ayurvedic empire is mixing herbs with spreadsheets. The dream? One lakh patients, global clinics, and profit margins strong enough to give allopaths heartburn. Grab your herbal tea—this earnings call had more punch than a kashayam shot. 🌿📈
2. At a Glance
Revenue ₹49.94 Cr (↑19.5% YoY): Ayurvedic growth—no modern medicine needed.
EBITDA ₹8.62 Cr (↑49.6%): When therapies cure patients and margins.
EBITDA Margin 17.3%: Discipline meets detox.
PAT ₹4.84 Cr (↑28%): Doctor’s orders: healthy profits.